Axinn Obtains Fourth Circuit Victory in Generic Celebrex® Case
December 17, 2014
At the U.S. Court of Appeals for the Fourth Circuit, Axinn obtained a victory that will help its client, Watson Laboratories (now Actavis), speed its generic version of Celebrex® to market.
An earlier lower court decision had effectively barred Watson Laboratories and others from bringing their drugs to market until June 2015.
Watson and Mylan Pharmaceuticals initially sued FDA in federal court, challenging an Agency letter decision that concluded that the companies were not eligible for a period of 180-day marketing exclusivity on the launch of their generic versions of Celebrex® because a reissued patent, according to FDA, was part of the same “bundle of rights” as an original patent. The U.S. District Court for the Northern District of West Virginia ruled in favor of the Agency, finding that the Agency’s interpretation of the statute regarding exclusivity periods was reasonable and was owed deference.
The Fourth Circuit Court of Appeals reversed and remanded the case, finding in favor of Axinn’s client and holding that FDA’s interpretation was contrary to the unambiguous statute.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Hanging in the Balance: Supreme Court Declines to Decide the Uninjured Class Member Question in Labcorp v. Davis
Axinn Viewpoints
Antitrust
New Incentives, New Rewards: What You Need to Know About the Antitrust Division’s First-Ever Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
How I Made Partner: 'Show Up and Build Rapport With Colleagues and Clients,' Says Michael O'Mara of Axinn Veltrop & Harkrider
Media Mentions
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property